The soluble form of pan-RTK inhibitor and tumor suppressor LRIG1 mediates downregulation of AXL through direct protein-protein interaction in glioblastoma.
Virginie NeirinckxAnn-Christin HauAnne SchusterSabrina FritahKatja TiemannEliane KleinPetr V NazarovAndré MatagneMartyna SzpakowskaMax MeyrathAndy ChevignéMirko H H SchmidtSimone P NiclouPublished in: Neuro-oncology advances (2019)
These results identify AXL as a novel sLRIG1 target and show that LRIG1-mediated RTK downregulation depends on direct protein interaction. The pan-RTK inhibitory activity of sLRIG1 warrants further investigation for new GBM treatment approaches.